Document is current
Any future updates will be listed below
-
Authors
Powell, Reid T. https://orcid.org/0000-0002-6242-8315
Rinkenbaugh, Amanda L. https://orcid.org/0000-0003-3276-6863
Guo, Lei
Cai, Shirong
Shao, Jiansu
Zhou, Xinhui
Zhang, Xiaomei https://orcid.org/0000-0003-0964-8922
Jeter-Jones, Sabrina
Fu, Chunxiao
Qi, Yuan https://orcid.org/0000-0001-9718-7593
Baameur Hancock, Faiza
White, Jason B.
Stephan, Clifford https://orcid.org/0000-0003-0657-6484
Davies, Peter J. https://orcid.org/0000-0003-0770-2796
Moulder, Stacy
Symmans, W. Fraser https://orcid.org/0000-0002-1526-184X
Chang, Jeffrey T. https://orcid.org/0000-0002-4578-5636
Piwnica-Worms, Helen https://orcid.org/0000-0003-4210-6738
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP150148)
Cancer Prevention and Research Institute of Texas (RP160710)
Cancer Prevention and Research Institute of Texas (RP200668)
Cancer Prevention and Research Institute of Texas (RP160710)
Cancer Prevention and Research Institute of Texas (RP160710)
- License Information
-
More Information
Article History
Received: 16 August 2023
Accepted: 9 May 2024
First Online: 27 May 2024
Competing interests
: S.L.M. is an employee of and holds stock in Eli Lilly. W.F.S. owns founder stock in Delphi Diagnostics and publicly traded stock in IONIS Pharmaceuticals and Eiger BioPharmaceuticals; is a consultant/advisor to Merck, Astra Zeneca; W.F.S. and C.F. are co-inventors of “Targeted Measure of Transcriptional Activity Related to Hormone Receptors”, United States, Patent No. 11,459,617; has received support for unrelated research from Pfizer; has nothing to disclose for travel, accommodations, expenses; and is an uncompensated scientific advisor to Delphi Diagnostics. All other authors have no competing financial or non-financial interests.
